Inhibiting p47phox is a rational therapeutic strategy to reduce oxidative stress for diseases where excessive ROS generation drives pathology, including cardiovascular disease, RA, neurodegeneration, metabolic disorders, and cancer. This evidence concerns the gene NCF1 and rheumatoid arthritis.